newsfilter
← Latest News
GlobeNewswire·

AIM ImmunoTech Reports First Quarter 2022 Financial Results and Provides Corporate Update

- First quarter marked by peer-reviewed journal and abstract publications showcasing statistically significant efficacy data of Ampligen in late-stage pancreatic cancer; results also showcased continued positive data in ovarian and triple-negative breast